AstraZenecaOxford

The AstraZenecaOxford COVID-19 vaccine, also known as ChAdOx1 nCoV-19 or NVX-CoV2373, is a viral vector vaccine developed by the University of Oxford and AstraZeneca. It was one of the first COVID-19 vaccines to enter clinical trials and receive emergency use authorization in several countries. The vaccine utilizes a chimpanzee adenovirus vector to deliver genetic material from the SARS-CoV-2 virus, prompting an immune response.

Development began in early 2020, with Phase III trials demonstrating significant efficacy in preventing symptomatic COVID-19 infection. Regulatory approvals followed rapidly in late 2020 and early 2021. The vaccine is administered in two doses, with a recommended interval between them. Its widespread deployment has been a key component of global vaccination efforts.

AstraZeneca's manufacturing and distribution strategy aimed for broad accessibility, particularly in low- and middle-income countries. While generally well-tolerated, some rare side effects have been reported, leading to specific usage recommendations and investigations in certain regions. The vaccine's contribution to mitigating the pandemic's impact has been substantial, though ongoing research continues to monitor its effectiveness against emerging variants and long-term immunity.

---